Brain+
0.155 DKK +27.16%1 investor is following this company
Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Denmark
BRAINP
Daily low / high price
0.128 / 0.161
DKK
Market cap
25.63M DKK
Turnover
272.7K DKK
Volume
1.9M
Financial calendar
Interim report
29.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Kim Baden-Kristensen | 15.4 % | 15.4 % |
Ulrik Ditlev Eriksen | 9.3 % | 9.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Brain+ A/S publishes the outcome of its rights issue of units
Brain+ A/S: Brain+ obtains additional guarantee commitment in its ongoing rights issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools